VC advancing the vaccine market in China has brought new development opportunities for health care reform – the vaccine market – pharmaceutical industries
China's economy to recover first in 2009, venture investment is clearly accelerated the rhythm of shots, the vaccine industry has become the investment community of the star. Since 2009, the vaccine industry concern, Sinovac successful switch plate Nasdaq, Jiangsu Simcere Pharmaceutical Holdings announced extension of application of biological, Novartis acquired A vaccination Zhejiang Tianyuan Bio manufacturers of these capital markets and foreign trade shows Medicine Giants, are accelerating the pace of entering the Chinese vaccine market.
New medical reform Bring development opportunities
Vaccine industry meet the many features of the venture capital industry's hobby. These features include: industry, large and rapid future growth, high barriers to entry, a large return on investment, exit channels and the time is ripe for such investment.
1, the scale of the vaccine industry: CITIC Securities, according to statistics, in 2008 the global vaccine market is 19.2 billion U.S. dollars, the Chinese vaccine market size of six billion yuan, becoming the world's third largest market for vaccines.
2, future industry growth: the growth of the vaccine industry is expected to come from new medical reform, the national vaccine stockpile and aggregate growth. New prevention-oriented health care reform is bound to bring opportunities to the vaccine market. Preliminary estimates for 2009 funding for basic public health services in China reached 19.5 billion yuan, while in 2011 will reach 26 billion yuan. Even if the growth rate calculated in accordance with the total vaccine market will reach more than 30% expansion.
3, industries with high thresholds: a high bio-pharmaceutical industry threshold. Industrial biotechnology is a very complex project, involving government, universities, research institutes and manufacturing enterprises, are also involved in basic, clinical, applied research, development, production Sell And the use of all aspects. A new vaccine strains from the R & D to market, usually 3-5 years.
4, investment returns and exit: A share market A flow Stocks sought after by investors, partly because a flow Epidemic On the other hand is due to the high-margin business. Analysis of the Shanghai and Shenzhen vaccine earnings data, you can see the vaccine manufacturers generally have more than 70% gross margin. In addition, the vaccine companies active in the capital market performance, so the risk of substantial return on investment, but also create more opportunities for their withdrawal.
5, the choice of investment timing: access to capital, it can venture explosive growth is an important basis for investment timing choice. New vaccines to market, companies are often able to bring hundreds of millions to billions of dollars selling. Vaccine research and development from the laboratory to the final listing of a number of years, the yield will be very difficult to predict when people appear more difficult to predict what the earnings will be orders of magnitude. As long as the tread on the point in time, venture capitalists can get the maximum benefit. Vaccine companies from China, look at the current earnings, the investment timing has gradually matured.
Fully consider the potential risks Venture capital investments in consideration when the vaccine industry, we must fully take into account its specific risk. Only fully anticipate the potential risks, and in a controlled situation, venture capital can be effectively locked future earnings.
First, industry fluctuations. Fluctuations in the vaccine industry from the volatility of the epidemic. In 2009 due to the spread of a stream, the Chinese Government carried out on a flu vaccine reserve, directly benefiting more than 10 manufacturers. However, the benefits of the epidemic wave, and will not last, to ensure steady and continuous growth in corporate profits, only through a rich product line, increase the category to erase a certain extent the risk of future earnings fluctuated wildly.
Followed a long cycle into big. Yunnan Watson companies as may become the first GEM vaccine companies and received extensive attention. After several rounds of tens of millions of company investment, until eight years later, have become a public company, the venture capital cycle is indeed rather long.
Third, the industry regulator.
I am a professional editor from China Manufacturers,
and my work is to promote a free online trade platform.
http://www.cheaponsale.com/ contain a great deal of information about
power rangers helmet , full face bmx helmets
welcome to visit!
Processing your request, Please wait....
